Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis

References

• Borisow N, Döring A, Pfueller CF, et al. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J. 2012;3:9.
   PubMedGoogle Scholar
• Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378:169–180.
   PubMed Web of Science ®Google Scholar
• Galetta SL, Villoslada P, Levin N, et al. Acute optic neuritis: unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflammation. 2015;2:e135.
   PubMed Web of Science ®Google Scholar
• Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol. 2014;10:447–458.
   PubMed Web of Science ®Google Scholar
• Krieger SC, Cook K, De Nino S, et al. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflammation. 2016;3:e279.
   PubMed Web of Science ®Google Scholar
• University of California, San Francisco MS-EPIC team: Cree BAC, Gourraud P-A, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499–510.
   PubMed Web of Science ®Google Scholar
• Veauthier C, Hasselmann H, Gold SM, et al. The Berlin treatment algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue [Internet]. 2016;7. [cited 2018 Jul 7]; Available from. Epma J. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121967/
   PubMed Web of Science ®Google Scholar
• Penner I-K, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol. 2017;13:662–675.
   PubMed Web of Science ®Google Scholar
• Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014;15:5–14.
   PubMed Web of Science ®Google Scholar
• Paul F. Pathology and MRI: exploring cognitive impairment in MS. Acta Neurol Scand. 2016;134(Suppl 200):24–33.
   PubMedGoogle Scholar
• Hasselmann H, Bellmann-Strobl J, Ricken R, et al. Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. Mult Scler J. 2016;22:1476–1484.
   PubMed Web of Science ®Google Scholar
• Gaede G, Tiede M, Lorenz I, et al. Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. Neurol Neuroimmunol Neuroinflammation. 2018;5:e423.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84:1165–1173.
   PubMed Web of Science ®Google Scholar
• Sinnecker T, Schumacher S, Mueller K, et al. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. Neurol Neuroimmunol Neuroinflammation. 2016;3:e259.
   PubMed Web of Science ®Google Scholar
• Blaabjerg M, Ruprecht K, Sinnecker T, et al. Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI. Neurol Neuroimmunol Neuroinflammation. 2016;3:e226.
   PubMed Web of Science ®Google Scholar
• Cipriani VP, Arndt N, Pytel P, et al. Effective treatment of CLIPPERS with long-term use of rituximab. Neurol Neuroimmunol Neuroinflammation. 2018;5:e448.
   PubMed Web of Science ®Google Scholar
• Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018;14:199–213.
   PubMed Web of Science ®Google Scholar
• Zeydan B, Gu X, Atkinson EJ, et al. Cervical spinal cord atrophy: an early marker of progressive MS onset. Neurol Neuroimmunol Neuroinflammation. 2018;5:e435.
   PubMed Web of Science ®Google Scholar
• Pawlitzki M, Neumann J, Kaufmann J, et al. Loss of corticospinal tract integrity in early MS disease stages. Neurol Neuroimmunol Neuroinflammation. 2017;4:e399.
   PubMed Web of Science ®Google Scholar
• Solomon AJ, Watts R, Dewey BE, et al. MRI evaluation of thalamic volume differentiates MS from common mimics. Neurol Neuroimmunol Neuroinflammation. 2017;4:e387.
   PubMed Web of Science ®Google Scholar
• Alcaide-Leon P, Cybulsky K, Sankar S, et al. Quantitative spinal cord MRI in radiologically isolated syndrome. Neurol Neuroimmunol Neuroinflammation. 2018;5:e436.
   PubMed Web of Science ®Google Scholar
• Parisi V, Manni G, Spadaro M, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. 1999;40:2520–2527.
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Oberwahrenbrock T, Brandt AU, et al. Optical coherence tomography for retinal imaging in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2014;153–162.
   Google Scholar
• Bock M, Paul F, Dörr J. Diagnosis and monitoring of multiple sclerosis: the value of optical coherence tomography. Nervenarzt. 2013;84:483–492.
   PubMed Web of Science ®Google Scholar
• Brandt AU, Martinez-Lapiscina EH, Nolan R, et al. Monitoring the course of MS with optical coherence tomography. Curr Treat Options Neurol. 2017;19:15.
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Brandt AU, Paul F. Optische Kohärenztomographie in der Neurologie – methodik und Anwendung in Forschung und Klinik. Klin Neurophysiol 2017; 48(04): 211-225.
   Google Scholar
• Brandt AU, Zimmermann H, Scheel M, et al. Untersuchungen des visuellen Systems in der Neurologie: aktuelle Forschung und klinische Relevanz. Aktuelle Neurol. 2017;44:27–45.
   Google Scholar
• Waldman AT, Liu GT, Lavery AM, et al. Optical coherence tomography and visual evoked potentials in pediatric MS. Neurol Neuroimmunol Neuroinflammation. 2017;4:e356.
   PubMed Web of Science ®Google Scholar
• Jindahra P, Hedges TR, Mendoza-Santiesteban CE, et al. Optical coherence tomography of the retina: applications in neurology. Curr Opin Neurol. 2010;23:16–23.
   PubMed Web of Science ®Google Scholar
• Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254:1178–1181.
   PubMed Web of Science ®Google Scholar
• Bock M, Brandt AU, Dörr J, et al. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler J. 2010;16:893–896.
   PubMed Web of Science ®Google Scholar
• Patel NB, Wheat JL, Rodriguez A, et al. Agreement between retinal nerve fiber layer measures from spectralis and cirrus spectral domain OCT. Optom Vis Sci. 2012;89:E652–E666.
   PubMed Web of Science ®Google Scholar
• Forooghian F, Cukras C, Meyerle CB, et al. Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci. 2008;49:4290–4296.
   PubMed Web of Science ®Google Scholar
• Yaqoob Z, Wu J, Yang C. Spectral domain optical coherence tomography: a better OCT imaging strategy. Biotechniques. 2005;39:S6–13.
   PubMedGoogle Scholar
• Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7:e34823.
   PubMed Web of Science ®Google Scholar
• Schippling S, Balk LJ, Costello F, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler J. 2015;21:163–170.
   PubMed Web of Science ®Google Scholar
• Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86:2303–2309.
   PubMed Web of Science ®Google Scholar
• Staurenghi G, Sadda S, Chakravarthy U, et al. Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN•OCT consensus. Ophthalmology. 2014;121:1572–1578.
   PubMed Web of Science ®Google Scholar
• Oberwahrenbrock T, Ringelstein M, Jentschke S, et al. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler J. 2013;19:1887–1895.
   PubMed Web of Science ®Google Scholar
• Oberwahrenbrock T, Traber GL, Lukas S, et al. Multicenter reliability of semiautomatic retinal layer segmentation using OCT. Neurol Neuroimmunol Neuroinflammation. 2018;5:e449.
   PubMed Web of Science ®Google Scholar
• Balcer LJ, Balk LJ, Brandt AU, et al. The international multiple sclerosis visual system consortium: advancing visual system research in multiple sclerosis. J Neuroophthalmol. 2018;38:494–501.
   PubMed Web of Science ®Google Scholar
• Oberwahrenbrock T, Weinhold M, Mikolajczak J, et al. Reliability of intra-retinal layer thickness estimates. PLoS One [Internet]. 2015;10. [cited 2015 Oct 29]; Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562656/
   PubMed Web of Science ®Google Scholar
• Galetta KM, Graves J, Talman LS, et al. Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study. J Neuro-Ophthalmol. 2012;32:116–123.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Zimmermann H, Mikolajczak J, et al. Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD. Neurol Neuroimmunol Neuroinflammation. 2017;4:e338.
   PubMed Web of Science ®Google Scholar
• Vecino E, Rodriguez FD, Ruzafa N, et al. Glia–neuron interactions in the mammalian retina. Prog Retin Eye Res. 2016;51:1–40.
   PubMed Web of Science ®Google Scholar
• Burkholder BM, Osborne B, Loguidice MJ, et al. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol. 2009;66:1366–1372.
   PubMedGoogle Scholar
• Costello F, Pan YI, Yeh EA, et al. The temporal evolution of structural and functional measures after acute optic neuritis. J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1369-73. doi: 10.1136/jnnp-2014-309704. Epub 2015 Feb 10.
   Web of Science ®Google Scholar
• Gelfand JM, Nolan R, Schwartz DM, et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain J Neurol. 2012;135:1786–1793.
   Google Scholar
• Knier B, Schmidt P, Aly L, et al. Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis. Brain J Neurol. 2016.
   Google Scholar
• Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol. 2012;11:963–972.
   PubMed Web of Science ®Google Scholar
• Al-Louzi OA, Bhargava P, Newsome SD, et al. Outer retinal changes following acute optic neuritis. Mult Scler J. 2016;22:362–372.
   PubMed Web of Science ®Google Scholar
• Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, et al. Dynamics of retinal injury after acute optic neuritis. Ann Neurol. 2015;77:517–528.
   PubMed Web of Science ®Google Scholar
• Hanson JVM, Hediger M, Manogaran P, et al. Outer retinal dysfunction in the absence of structural abnormalities in multiple sclerosis. Invest Ophthalmol Vis Sci. 2018;59:549–560.
   Web of Science ®Google Scholar
• Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13:83–99.
   PubMed Web of Science ®Google Scholar
• Britze J, Pihl-Jensen G, Frederiksen JL. Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol. 2017;264:1837–1853.
   PubMed Web of Science ®Google Scholar
• Bock M, Brandt AU, Dörr J, et al. Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg. 2010;112:647–652.
   PubMed Web of Science ®Google Scholar
• Outteryck O, Majed B, Defoort-Dhellemmes S, et al. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler J. 2015;21:1781–1793.
   PubMed Web of Science ®Google Scholar
• Brandt AU, Specovius S, Oberwahrenbrock T, et al. Frequent retinal ganglion cell damage after acute optic neuritis. Mult Scler Relat Disord. 2018;22:141–147.
   PubMed Web of Science ®Google Scholar
• Nolan RC, Galetta SL, Frohman TC, et al. Optimal intereye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in multiple sclerosis. J Neuroophthalmol. 2018 Dec;38(4):451-458. doi: 10.1097/WNO.0000000000000629.
   Web of Science ®Google Scholar
• Coric D, Balk LJ, Uitdehaag BMJ, et al. Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis. Eur J Neurol. 2017;24:1479–1484.
   PubMed Web of Science ®Google Scholar
• Schematic Figure – Retina (Creative Commons License) – Neurodiagnostics Laboratory [Internet]. [ cited 2017 Aug 25]. Available from: http://neurodial.de/2017/08/25/schematic-figure-retina-creative-commons-license/
   Google Scholar
• Schematic Figure – Macular OCT with Intraretinal Layers (Creative Commons License) – Neurodiagnostics Laboratory. [Internet]. [cited 2017 Oct 22]. Available from: http://neurodial.de/2017/08/25/schematic-figure-macular-oct-with-intraretinal-layers/
   Google Scholar
• Gelfand JM, Cree BA, Nolan R, et al. Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol. 2013;70:629–633.
   PubMed Web of Science ®Google Scholar
• Brandt AU, Oberwahrenbrock T, Kadas EM, et al. Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology. 2014;83:73–77.
   PubMed Web of Science ®Google Scholar
• Heesen C, Böhm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler J. 2008;14:988–991.
   PubMed Web of Science ®Google Scholar
• Bock M, Brandt AU, Kuchenbecker J, et al. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol. 2012;96:62–67.
   PubMed Web of Science ®Google Scholar
• Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59:963–969.
   PubMed Web of Science ®Google Scholar
• Walter SD, Ishikawa H, Galetta KM, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. 2012;119:1250–1257.
   PubMed Web of Science ®Google Scholar
• Schinzel J, Zimmermann H, Paul F, et al. Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurol. 2014;14:31.
   PubMed Web of Science ®Google Scholar
• Mowry EM, Loguidice MJ, Daniels AB, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009;80:767–772.
   PubMed Web of Science ®Google Scholar
• Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006;113:324–332.
   PubMed Web of Science ®Google Scholar
• Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology. 2010;74(Suppl 3):S16–23.
   PubMedGoogle Scholar
• Di Maggio G, Santangelo R, Guerrieri S, et al. Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis? Mult Scler J. 2014;20:1342–1347.
   PubMed Web of Science ®Google Scholar
• Almarcegui C, Dolz I, Pueyo V, et al. Correlation between functional and structural assessments of the optic nerve and retina in multiple sclerosis patients. Neurophysiol Clin Clin Neurophysiol. 2010;40:129–135.
   PubMed Web of Science ®Google Scholar
• Tugcu B, Soysal A, Kılıc M, et al. Assessment of structural and functıonal vısual outcomes ın relapsıng remıttıng multıple sclerosıs wıth vısual evoked potentıals and optıcal coherence tomography. J Neurol Sci. 2013;335:182–185.
   PubMed Web of Science ®Google Scholar
• Klistorner A, Arvind H, Nguyen T, et al. Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol Adv Ophthalmol. 2009;118:129–137.
   PubMed Web of Science ®Google Scholar
• Alshowaeir D, Yannikas C, Garrick R, et al. Multifocal VEP assessment of optic neuritis evolution. Clin Neurophysiol. 2015;126:1617–1623.
   PubMed Web of Science ®Google Scholar
• Frohman AR, Schnurman Z, Conger A, et al. Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. Neurology. 2012;79:797–801.
   PubMed Web of Science ®Google Scholar
• Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16:797–812.
   PubMed Web of Science ®Google Scholar
• Oberwahrenbrock T, Schippling S, Ringelstein M, et al. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography.Mult Scler Int [Internet]. 2012;2012. [cited 2015 Oct 29]; Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410317/
   PubMedGoogle Scholar
• Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, et al. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology. 2007;68:1488–1494.
   PubMed Web of Science ®Google Scholar
• You Y, Graham EC, Shen T, et al. Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. Neurol Neuroimmunol Neuroinflammation. 2018;5:e427.
   PubMed Web of Science ®Google Scholar
• Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9:921–932.
   PubMed Web of Science ®Google Scholar
• Klistorner A, Sriram P, Vootakuru N, et al. Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. Neurology. 2014;82:2165–2172.
   PubMed Web of Science ®Google Scholar
• Sinnecker T, Oberwahrenbrock T, Metz I, et al. Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning–an ultrahigh-field MR pilot study. Eur Radiol. 2015;25:122–131.
   PubMed Web of Science ®Google Scholar
• Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69:1603–1609.
   PubMed Web of Science ®Google Scholar
• Pfueller CF, Brandt AU, Schubert F, et al. Metabolic changes in the visual cortex are linked to retinal nerve fiber layer thinning in multiple sclerosis. PLoS One. 2011;6:e18019.
   PubMed Web of Science ®Google Scholar
• Dörr J, Wernecke KD, Bock M, et al. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS One. 2011;6:e18132.
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Freing A, Kaufhold F, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler J. 2013;19:443–450.
   PubMed Web of Science ®Google Scholar
• Saidha S, Sotirchos ES, Oh J, et al. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol. 2013;70:34–43.
   PubMed Web of Science ®Google Scholar
• Saidha S, Al-Louzi O, Ratchford JN, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study. Ann Neurol. 2015;78:801–813.
   PubMed Web of Science ®Google Scholar
• Balk LJ, Steenwijk MD, Tewarie P, et al. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:419–424.
   PubMed Web of Science ®Google Scholar
• Saidha S, Syc SB, Ibrahim MA, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain J Neurol. 2011;134:518–533.
   Google Scholar
• Saidha S, Calabresi PA. Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: yes. Mult Scler. 2014;20:1296–1298.
   PubMed Web of Science ®Google Scholar
• Alonso R, Gonzalez-Moron D, Garcea O. Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: a review. Mult Scler Relat Disord. 2018;22:77–82.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang Q, Thorell MR, et al. Swept-source OCT angiography of the retinal vasculature using intensity differentiation-based optical microangiography algorithms. Ophthalmic Surg Lasers Imaging Retina. 2014;45:382–389.
   PubMed Web of Science ®Google Scholar
• Wang L, Murphy O, Caldito NG, et al. Emerging applications of Optical Coherence Tomography Angiography (OCTA) in neurological research. Eye Vis Lond Engl. 2018;5:11.
   PubMedGoogle Scholar
• Britze J, Frederiksen JL. Optical coherence tomography in multiple sclerosis. Eye. 2018;32:884–888.
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Cennamo G, Criscuolo C, et al. Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. Mult Scler. 2018;24:1706–1714.
   PubMed Web of Science ®Google Scholar
• Feucht N, Maier M, Lepennetier G, et al. Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009. [Epub ahead of print].
   Google Scholar
• Lanzillo R, Cennamo G, Moccia M, et al. Retinal vascular density in multiple sclerosis: a 1-year follow-up. Eur J Neurol. 2019 Jan;26(1):198-201. doi: 10.1111/ene.13770. Epub 2018 Sep 3.
   Web of Science ®Google Scholar
• Spain RI, Liu L, Zhang X, et al. Optical coherence tomography angiography enhances the detection of optic nerve damage in multiple sclerosis. Br J Ophthalmol. 2018;102:520–524.
   PubMed Web of Science ®Google Scholar
• Wang X, Jia Y, Spain R, et al. Optical coherence tomography angiography of optic nerve head and parafovea in multiple sclerosis. Br J Ophthalmol. 2014;98:1368–1373.
   PubMed Web of Science ®Google Scholar
• Plumb J, McQuaid S, Mirakhur M, et al. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol Zurich Switz. 2002;12:154–169.
   PubMed Web of Science ®Google Scholar
• Zeis T, Graumann U, Reynolds R, et al. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain J Neurol. 2008;131:288–303.
   Google Scholar
• Grazioli E, Zivadinov R, Weinstock-Guttman B, et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci. 2008;268:12–17.
   PubMed Web of Science ®Google Scholar
• Siger M, Dziegielewski K, Jasek L, et al. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol. 2008;255:1555–1560.
   PubMed Web of Science ®Google Scholar
• Young KL, Brandt AU, Petzold A, et al. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis. Eur J Neurol. 2013;20:803–811.
   PubMed Web of Science ®Google Scholar
• Maghzi A-H, Graves J, Revirajan N, et al. Retinal axonal loss in very early stages of multiple sclerosis. Eur J Neurol. 2015;22:1138–1141.
   PubMedGoogle Scholar
• Raz N, Bick AS, Ben-Hur T, et al. Focal demyelinative damage and neighboring white matter integrity: an optic neuritis study. Mult Scler. 2015;21:562–571.
   PubMed Web of Science ®Google Scholar
• Dasenbrock HH, Smith SA, Ozturk A, et al. Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability. J Neuroimaging. 2011;21:e41–49.
   PubMed Web of Science ®Google Scholar
• van der Walt A, Kolbe SC, Wang YE, et al. Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes. PLoS One. 2013;8:e83825.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Xu J, Tutlam NT, et al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. Arch Neurol. 2012;69:65–71.
   PubMedGoogle Scholar
• Kuchling J, Brandt AU, Paul F, et al. Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. EPMA J. 2017;8:279–294.
   PubMed Web of Science ®Google Scholar
• Kuchling J, Backner Y, Oertel FC, et al. Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. NeuroImage Clin [Internet]. [cited 2018 May 11]; Available from: https://www.sciencedirect.com/science/article/pii/S2213158218301505
   PubMed Web of Science ®Google Scholar
• Backner Y, Kuchling J, Massarwa S, et al. Anatomical wiring and functional networking changes in the visual system following optic neuritis. JAMA Neurol. 2018;75:287–295.
   PubMed Web of Science ®Google Scholar
• Oh J, Sotirchos ES, Saidha S, et al. Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. Neurology. 2015;84:720–728.
   PubMedGoogle Scholar
• Sotirchos ES, Saidha S. OCT is an alternative to MRI for monitoring MS - YES. Mult Scler. 2018;24:701–703.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Ciccarelli O, et al. Mri criteria for the diagnosis of multiple sclerosis: magnims consensus guidelines. Lancet Neurol. 2016;15:292–303.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–164.
   PubMed Web of Science ®Google Scholar
• Stellmann J-P, Krumbholz M, Friede T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88:639–647.
   PubMed Web of Science ®Google Scholar
• Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol. 2014;261:1–16.
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Schöllhammer J, Hoepner R, et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol. 2016;263:575–582.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79:206–216.
   PubMed Web of Science ®Google Scholar
• Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21:845–853.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239–245.
   PubMedGoogle Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflammation. 2018;5:e504.
   PubMed Web of Science ®Google Scholar
• Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflammation. 2015;2:e110.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Kim S-H, Schmidt F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler Houndmills Basingstoke Engl. 2018 Nov;24(13):1737-1742. doi: 10.1177/1352458517730131. Epub 2017 Aug 31.
   Google Scholar
• Gahlen A, Trampe A-K, Haupeltshofer S, et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflammation. 2017;4:e363.
   PubMed Web of Science ®Google Scholar
• Asgari N, Flanagan EP, Fujihara K, et al. Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation. 2017;4:e343.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflammation. 2017;4:e311.
   PubMed Web of Science ®Google Scholar
• Chavarro VS, Mealy MA, Simpson A, et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation. 2016;3:e286.
   PubMed Web of Science ®Google Scholar
• Finke C, Heine J, Pache F, et al. Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. Neurol Neuroimmunol Neuroinflammation. 2016;3:e229.
   PubMed Web of Science ®Google Scholar
• Metz I, Beißbarth T, Ellenberger D, et al. Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2016;3:e204.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Fechner K, et al. Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation. 2014;11:129.
   PubMed Web of Science ®Google Scholar
• Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016;87:1005–1015.
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2018.
   Web of Science ®Google Scholar
• Daneman R. Finding NMO. Neurol Neuroimmunol Neuroinflammation. 2017;4:e313.
   PubMed Web of Science ®Google Scholar
• Borisow N, Hellwig K, Paul F. Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalised treatment strategies. EPMA J 2018. inpress.
   PubMed Web of Science ®Google Scholar
• Chien C, Scheel M, Schmitz-Hübsch T, et al. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler J. 2018;1352458518815596. [Ahead of print].
   Google Scholar
• Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One. [Internet]. 2013:8. [cited 2015 Oct 29]; Available from. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689687/
   Web of Science ®Google Scholar
• Schmidt F, Zimmermann H, Mikolajczak J, et al. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2017;11:45–50.
   PubMed Web of Science ®Google Scholar
• Bichuetti DB, de Camargo AS, Falcão AB, et al. The retinal nerve fiber layer of patients with neuromyelitis optica and chronic relapsing optic neuritis is more severely damaged than patients with multiple sclerosis. J Neuroophthalmol. 2013;33:220–224.
   PubMed Web of Science ®Google Scholar
• Cheng L, Wang J, He X, et al. Macular changes of neuromyelitis optica through spectral-domain optical coherence tomography. Int J Ophthalmol. 2016;9:1638–1645.
   PubMed Web of Science ®Google Scholar
• Fernandes DB, Raza AS, Nogueira R, et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology. 2013;120:387–394.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Kleiter I, Ayzenberg I, et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler. 2014;20:617–620.
   PubMedGoogle Scholar
• Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21:678–688.
   PubMed Web of Science ®Google Scholar
• Finke C, et al. JAMA Neurol. 2018 Mar 1;75(3):296-303. doi:10.1001/jamaneurol.2017.3890.
   Google Scholar
• Kaufhold F, Zimmermann H, Schneider E, et al. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS One. [Internet]. 2013 [cited 2015 Oct 29];8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735514/
   Web of Science ®Google Scholar
• Oertel FC, Zimmermann H, Paul F, et al. Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. EPMA J. 2018;9:21–33.
   PubMed Web of Science ®Google Scholar
• Syc SB, Saidha S, Newsome SD, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain J Neurol. 2012;135:521–533.
   Google Scholar
• Oertel FC, Havla J, Roca-Fernández A, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1259-1265. doi: 10.1136/jnnp-2018-318382. Epub 2018 Jun 19.
   Web of Science ®Google Scholar
• Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody–seropositive NMOSD. Neurol Neuroimmunol Neuroinflammation. 2017;4:e334.
   PubMed Web of Science ®Google Scholar
• Jeong IH, Kim HJ, Kim N-H, et al. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. J Neurol. 2016;263:1343–1348.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Nakashima I. Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy? Neurol Neuroimmunol Neuroinflammation. 2017;4:e347.
   PubMed Web of Science ®Google Scholar
• Ventura RE, Kister I, Chung S, et al. Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflammation. 2016;3:e224.
   PubMed Web of Science ®Google Scholar
• Zhao -D-D, Zhou H-Y, Wu Q-Z, et al. Diffusion tensor imaging characterization of occult brain damage in relapsing neuromyelitis optica using 3.0T magnetic resonance imaging techniques. Neuroimage. 2012;59:3173–3177.
   PubMed Web of Science ®Google Scholar
• Felix CM, Levin MH, Verkman AS. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflammation. 2016;13:275.
   PubMed Web of Science ®Google Scholar
• Yadav SK, Motamedi S, Oberwahrenbrock T, et al. CuBe: parametric modeling of 3D foveal shape using cubic Bézier. Biomed Opt Express. 2017;8:4181–4199.
   PubMed Web of Science ®Google Scholar
• Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflammation. 2015;2:e89.
   PubMed Web of Science ®Google Scholar
• Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflammation. 2015;2:e62.
   PubMed Web of Science ®Google Scholar
• Kim S-M, Woodhall MR, Kim J-S, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation. 2015;2:e163.
   PubMed Web of Science ®Google Scholar
• Chalmoukou K, Alexopoulos H, Akrivou S, et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation. 2015;2:e131.
   PubMed Web of Science ®Google Scholar
• Hacohen Y, Palace J. Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. Neurology. 2018.
   Web of Science ®Google Scholar
• Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15:134.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and labora tory features, treatment, and long-term outcome. forthcoming.
   Google Scholar
• Körtvélyessy P, Breu M, Pawlitzki M, et al. ADEM-like presentation, anti-MOG antibodies, and MS pathology: two case reports. Neurol Neuroimmunol Neuroinflammation. 2017;4:e335.
   PubMed Web of Science ®Google Scholar
• Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2016;3:e257.
   PubMed Web of Science ®Google Scholar
• Dos Passos GR, Oliveira LM, Da Costa BK, et al. MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol. 2018;9:217.
   PubMed Web of Science ®Google Scholar
• Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66–72.
   PubMed Web of Science ®Google Scholar
• Borisow N, Mori M, Kuwabara S, et al. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:888.
   PubMed Web of Science ®Google Scholar
• Pandit L, Mustafa S, Uppoor R, et al. Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis. Neurol Neuroimmunol Neuroinflammation. 2018;5:e412.
   PubMed Web of Science ®Google Scholar
• Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflammation. 2017;4:e322.
   PubMed Web of Science ®Google Scholar
• Hamid SHM, Whittam D, Saviour M, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018;75:65–71.
   PubMed Web of Science ®Google Scholar
• Pache F, Zimmermann H, Mikolajczak J, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation [Internet]. 2016:13. [cited 2016 Nov 16]; Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088645/
   Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.
   PubMed Web of Science ®Google Scholar
• Sepulveda JA, Turpin A, McKendrick AM. Individual differences in foveal shape: feasibility of individual maps between structure and function within the macular regionindividual differences in foveal shape. Invest Ophthalmol Vis Sci. 2016;57:4772–4778.
   PubMed Web of Science ®Google Scholar
• Havla J, Kümpfel T, Schinner R, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017;264:139–151.
   PubMed Web of Science ®Google Scholar
• Kleffner I, Dörr J, Ringelstein M, et al. Diagnostic criteria for Susac syndrome. J Neurol Neurosurg Psychiatry. 2016;87:1287–1295.
   PubMed Web of Science ®Google Scholar
• Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. Neurology. 1979;29:313–316.
   PubMed Web of Science ®Google Scholar
• Dörr J, Krautwald S, Wildemann B, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol. 2013;9:307–316.
   PubMed Web of Science ®Google Scholar
• Dörr J, Radbruch H, Bock M, et al. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol. 2009;5:683–688.
   PubMed Web of Science ®Google Scholar
• Jarius S, Kleffner I, Dörr JM, et al. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation. 2014;11:46.
   PubMed Web of Science ®Google Scholar
• Martinet N, Fardeau C, Adam R, et al. Fluorescein and indocyanine green angiographies in Susac syndrome. Retina (Philadelphia, Pa). 2007;27:1238–1242.
   PubMed Web of Science ®Google Scholar
• Brandt AU, Zimmermann H, Kaufhold F, et al. Patterns of retinal damage facilitate differential diagnosis between susac syndrome and MS. PLoS One [Internet]. 2012:7. [cited 2015 Oct 29]; Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372471/
   Web of Science ®Google Scholar
• Brandt AU, Oberwahrenbrock T, Costello F, et al. Retinal lesion evolution in susac syndromE. Retina Phila. Pa. 2015.
   Google Scholar
• Kashani AH, Chen C-L, Gahm JK, et al. Optical coherence tomography angiography: a comprehensive review of current methods and clinical applications. Prog Retin Eye Res. 2017;60:66–100.
   PubMed Web of Science ®Google Scholar
• García-Serrano JL, Muñoz de Escalona-Rojas JE, Callejas-Rubio JL, et al. Optical coherence tomography angiography in the early diagnosis of Susac syndrome. Neurol Barc Spain. 2017 Sep 25. pii: S0213-4853(17)30274-8. doi: 10.1016/j.nrl.2017.07.014. [Epub ahead of print].
   Google Scholar
• Reznicek L, Klein T, Wieser W, et al. Megahertz ultra-wide-field swept-source retina optical coherence tomography compared to current existing imaging devices. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2014;252:1009–1016.
   PubMed Web of Science ®Google Scholar
• Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18:108–112.
   PubMed Web of Science ®Google Scholar
• Algahtani H, Shirah B, Amin M, et al. Susac syndrome misdiagnosed as multiple sclerosis with exacerbation by interferon beta therapy. Neuroradiol J. 2018;31:207–212.
   PubMed Web of Science ®Google Scholar
• Zhovtis Ryerson L, Kister I, Snuderl M, et al. Incomplete Susac syndrome exacerbated after natalizumab. Neurol Neuroimmunol Neuroinflammation. 2015;2:e151.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Cotter J, Klingman J, et al. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflammation. 2014;1:e34.
   PubMedGoogle Scholar
• Fujihara K, Nakashima I. Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy? Neurol Neuroimmunol Neuroinflammation. 2014;1:e38.
   PubMedGoogle Scholar
• Martinez-Lapiscina EH, Arnow S, Wilson JA, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016;15:574–584.
   PubMed Web of Science ®Google Scholar
• Bsteh G, Hegen H, Teuchner B, et al. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216. [Epub ahead of print].
   Google Scholar
• Zimmermann HG, Knier B, Oberwahrenbrock T, et al. Association of retinal ganglion cell layer thickness with future disease activity in patients with clinically isolated syndrome. JAMA Neurol. [Internet]. 2018 [cited 2018 Apr 27]; Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2679108.
   Web of Science ®Google Scholar
• Knier B, Leppenetier G, Wetzlmair C, et al. Association of retinal architecture, intrathecal immunity, and clinical course in multiple sclerosis. JAMA Neurol. 2017;74:847–856.
   PubMed Web of Science ®Google Scholar
• Knier B, Berthele A, Buck D, et al. Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination. Mult Scler J. 2016;22:893–900.
   PubMed Web of Science ®Google Scholar
• Wicki CA, Hanson JVM, Schippling S. Optical coherence tomography as a means to characterize visual pathway involvement in multiple sclerosis. Curr Opin Neurol. 2018;31:662–668.
   PubMedGoogle Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189–199.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflammation. 2014;1:e18.
   PubMedGoogle Scholar
• Ranger A, Ray S, Szak S, et al. Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies. Neurol Neuroimmunol Neuroinflammation. 2018;5:e417.
   PubMed Web of Science ®Google Scholar
• Raftopoulos R, Hickman SJ, Toosy A, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:259–269.
   PubMed Web of Science ®Google Scholar
• Esfahani MR, Harandi ZA, Movasat M, et al. Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2012;250:863–869.
   PubMed Web of Science ®Google Scholar
• Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet Lond Engl. 2017;390:2481–2489.
   PubMed Web of Science ®Google Scholar
• K-W Sühs, Hein K, Sättler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012;72:199–210.
   PubMed Web of Science ®Google Scholar
• Diem R, Molnar F, Beisse F, et al. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open. 2016;6:e010956.
   PubMed Web of Science ®Google Scholar
• McKee JB, Elston J, Evangelou N, et al. Amiloride clinical trial in optic neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial. BMJ Open. 2015;5:e009200.
   PubMed Web of Science ®Google Scholar
• Sergott RC, Bennett JL, Rieckmann P, et al. ATON: results from a phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. J Neurol Sci. 2015;351:174–178.
   PubMed Web of Science ®Google Scholar
• Kappos L, Hartung H-P, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13:353–363.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Coffey CS, Cudkowicz ME, et al. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp Clin Trials. 2016;50:166–177.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Coffey CS, Conwit R, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379:846–855.
   PubMed Web of Science ®Google Scholar
• Cambron M, Mostert J, Haentjens P, et al. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial. Trials. 2014;15:37.
   PubMedGoogle Scholar
• Shirani A, Okuda DT, Therapeutic advances so. Future prospects in progressive forms of multiple sclerosis. Neurother J Am Soc Exp Neurother. 2016;13:58–69.
   Google Scholar
• Rice CM, Marks DI, Ben-Shlomo Y, et al. Assessment of bone marrow-derived cellular therapy in progressive multiple sclerosis (ACTiMuS): study protocol for a randomised controlled trial. Trials. 2015;16:463.
   PubMed Web of Science ®Google Scholar
• Dörr J, Ohlraun S, Skarabis H, et al. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS trial): study protocol for a randomized controlled trial. Trials. 2012;13:15.
   PubMed Web of Science ®Google Scholar
• Soelberg K, Jarius S, Skejoe H, et al. A population-based prospective study of optic neuritis. Mult Scler. 2017;23:1893–1901.
   PubMed Web of Science ®Google Scholar
• Henderson APD, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain. 2010;133:2592–2602.
   PubMed Web of Science ®Google Scholar
• Balk LJ, Cruz-Herranz A, Albrecht P, et al. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016;263:1323–1331.
   PubMed Web of Science ®Google Scholar
• Kaufhold F, Kadas EM, Schmidt C, et al. Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT. PLoS One [Internet]. 2012:7. [cited 2015 Oct 29]; Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352870/
   Web of Science ®Google Scholar
• Oertel FC, Bosello F, Petzold A. Retinal optical coherence tomography shows optic disc changes in low intracranial pressure headaches: a case report. Acta Neurol Belg. 2018 Mar;118(1):131-133. doi: 10.1007/s13760-017-0878-4. Epub 2018 Jan 3.
   Web of Science ®Google Scholar
• Brandt AU, Oberwahrenbrock T, Mikolajczak J, et al. Visual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflammation. 2016;3:e198.
   PubMed Web of Science ®Google Scholar
• Roth NM, Saidha S, Zimmermann H, et al. Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20:1170–1176.
   PubMed Web of Science ®Google Scholar
• Roth NM, Saidha S, Zimmermann H, et al. Photoreceptor layer thinning in idiopathic Parkinson’s disease. Mov Disord. 2014;29:1163–1170.
   PubMed Web of Science ®Google Scholar
• Albrecht P, Blasberg C, Lukas S, et al. Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. Neurology. 2015;85:521–527.
   PubMed Web of Science ®Google Scholar
• Ewering C, Haşal N, Alten F, et al. Temporal retinal nerve fibre layer thinning in cluster headache patients detected by optical coherence tomography. Cephalalgia Int J Headache. 2015;35:946–958.
   PubMed Web of Science ®Google Scholar
• Alten F, Motte J, Ewering C, et al. Multimodal retinal vessel analysis in CADASIL patients. PLoS One. 2014;9:e112311.
   PubMedGoogle Scholar
• Albrecht P, Blasberg C, Ringelstein M, et al. Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. J Neurol. 2017;264:1370–1380.
   PubMed Web of Science ®Google Scholar
• Stricker S, Oberwahrenbrock T, Zimmermann H, et al. Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1. PLoS One. 2011;6:e23024.
   PubMed Web of Science ®Google Scholar
• Yadav SK, Kadas EM, Motamedi S, et al. Optic nerve head three-dimensional shape analysis. J Biomed Opt. 2018;23:1–13.
   PubMed Web of Science ®Google Scholar
• Pircher M, Zawadzki RJ. Review of adaptive optics OCT (AO-OCT): principles and applications for retinal imaging [Invited]. Biomed Opt Express. 2017;8:2536–2562.
   PubMed Web of Science ®Google Scholar
• Liu Z, Kurokawa K, Zhang F, et al. Imaging and quantifying ganglion cells and other transparent neurons in the living human retina. Proc Natl Acad Sci USA. 2017;114:12803–12808.
   PubMed Web of Science ®Google Scholar
• Fauw JD, Ledsam JR, Romera-Paredes B, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24:1342–1350.
   PubMed Web of Science ®Google Scholar